Importance Stroke is the fifth leading cause of death and a leading cause of disability in the
United States, affecting nearly 800 000 individuals annually. Observations Sudden …

Purpose—To critically review and evaluate the science behind individual eligibility criteria
(indication/inclusion and contraindications/exclusion criteria) for intravenous recombinant …

Intravenous thrombolysis is the only approved systemic reperfusion treatment for patients
with acute ischaemic stroke. These European Stroke Organisation (ESO) guidelines provide …

Background Thrombolysis for acute ischaemic stroke has been investigated in several
clinical trials, with variable results. We have assessed the safety and efficacy of intravenous …

Background Computed tomography (CT) must be done before thrombolytic treatment of
hyperacute ischaemic stroke, but the significance of early ischaemic change on CT is …

Purpose—Our goal is to provide an overview of the current evidence about components of
the evaluation and treatment of adults with acute ischemic stroke. The intended audience is …

ContextIntravenous tissue-type plasminogen activator can be beneficial to some patients
when given within 3 hours of stroke onset, but many patients present later after stroke onset …

Background Most strokes are due to blockage of an artery in the brain by a blood clot.
Prompt treatment with thrombolytic drugs can restore blood flow before major brain damage …

This article represents the update of the European Stroke Initiative Recommendations for
Stroke Management. These guidelines cover both ischaemic stroke and transient ischaemic …

BACKGROUND AND PURPOSE: Clinicians are insecure reading CT scans by using the
one-third rule for acute middle cerebral artery stroke (1/3 MCA rule) before treating patients …